Michael Lind
Impact in
- Oncology top 2%
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Drug Transport and Resistance Mechanisms
-
- Chemotherapy-induced organ toxicity mitigation
Papers in
- Oncology 43
- Lung Cancer Research Studies 13
- Cancer Treatment and Pharmacology 7
-
- Cancer therapeutics and mechanisms 9
- Ubiquitin and proteasome pathways 5
- Co-authors
- Lynn Cawkwell (33 shared papers)Philip Drew (13 shared papers)Lawrence K. Duffy (1 shared paper)Daniel A. Kirschner (1 shared paper)Dennis J. Selkoe (1 shared paper)Laura Smith (8 shared papers)Alison J. Sinclair (1 shared paper)Hideyo Inouye (1 shared paper)
- Journals
- Cancer Chemotherapy and Pharmacology (11 papers)European Journal of Cancer (8 papers)Annals of Oncology (5 papers)British Journal of Cancer (5 papers)Journal of Clinical Oncology (5 papers)
- Partner nations
- United KingdomUnited StatesAustralia
In The Last Decade
Michael Lind
106 papers receiving 3.4k citations
Peers
Comparison fields: 5 of 129
- Oncology 935
- Pathology and Forensic Medicine 378
- Cancer Research 309
- Transplantation 52
- Pharmacology 153
Countries citing papers authored by Michael Lind
This map shows the geographic impact of Michael Lind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Lind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Lind more than expected).
Fields of papers citing papers by Michael Lind
This network shows the impact of papers produced by Michael Lind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Lind. The network helps show where Michael Lind may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Lind, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 112 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1987 | 415 | |
| 2 | 2006 | 192 | |
| 3 | 1981 | 159 | |
| 4 | 2006 | 153 | |
| 5 | 2013 | 153 | |
| 6 | 2004 | 116 | |
| 7 | 1988 | 112 | |
| 8 | 1994 | 105 | |
| 9 | 2004 | 105 | |
| 10 | A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. | 1998 | 78 |
| 11 | 1989 | 74 | |
| 12 | 1989 | 59 | |
| 13 | 2001 | 57 | |
| 14 | 1989 | 55 | |
| 15 | 2020 | 50 | |
| 16 | 2007 | 50 | |
| 17 | 1990 | 49 | |
| 18 | 2009 | 44 | |
| 19 | 1989 | 44 | |
| 20 | 2008 | 44 |
About Michael Lind
Michael Lind is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Cancer Research, having authored 112 papers that have together received 3.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Research Studies (13 papers), Chemotherapy-induced organ toxicity mitigation (12 papers), Cancer therapeutics and mechanisms (9 papers), Occupational and environmental lung diseases (8 papers), Neuroendocrine Tumor Research Advances (7 papers), Cancer Treatment and Pharmacology (7 papers) and Ubiquitin and proteasome pathways (5 papers). The work is most often cited by research in Oncology (935 citations), Pathology and Forensic Medicine (378 citations), Cancer Research (309 citations), Transplantation (52 citations) and Pharmacology (153 citations). Michael Lind has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Lynn Cawkwell, Philip Drew, Lawrence K. Duffy, Daniel A. Kirschner, Dennis J. Selkoe, Laura Smith, Alison J. Sinclair, Hideyo Inouye, Mark B. Watson and Sara L. O’Kane. Their work appears in journals such as Cancer Chemotherapy and Pharmacology, European Journal of Cancer, Annals of Oncology, British Journal of Cancer and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.